Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT-747 + URSO in Primary Biliary Cirrhosis
NCT00550862Phase 2Terminated
- Sponsor
- Intercept Pharmaceuticals
- Start
- Oct 2007
- Primary completion
- Aug 2009
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 2 trial of obeticholic acid in primary biliary cholangitis (PBC), sponsored by Intercept Pharmaceuticals. Started Oct 2007; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT00550862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550862.